The Andean Country authorized the commercialization of Vedevax Block, the first recombinant vaccine for the control of the virus. The product developed by Bioinnovo SA, a company created by a partnership between the National Institute of Agricultural Technology (INTA) of Argentina and the company Vetanco…
Bioinnovo, the public-private company (INTA–Vetanco) made its first contribution to the macro collaborative project conducted by a scientific committee that brings together more than twenty male and female researchers from different institutions. Those institutions are the Institute of Science and Technology César Milstein (Conicet –…
Following the signing of a Memorandum of Understanding/Cooperation Agreement (MOU) between the MIT startup Sunflower and Bioinnovo, Kerry Love, PhD and Laura Crowell, PhD visited Vetanco at its corporate headquarters. The purpose of the meeting was to ratify the MOU, which detailed the scope of work optimizing several innovative platforms using…
Argentina’s Bioinnovo has updated its partnership with Spanish firm Algenex for the use of a molecule developed by the latter The renewed partnership provides Bioinnovo with the international rights to use Algenex’s APCH (antigen presenting cells homing) molecule in the _eld of animal health. Bioinnovo…
Bioinnovo, the technology-based public-private company formed by the National Institute of Agricultural Technology (INTA) and Vetanco SA, agree to renew their contract with Algenex for the use of the APCH molecule, the targeting protein of the innovative vaccine Vedevax BLOCK. After many years of successful…
Representatives of Vetanco met with university authorities to discuss a license contract for a recombinant vaccine, with the aim of marketing it in all American countries. Four professionals from Vetanco Argentina, headed by its president Jorge Winokur, visited the University of Concepción, Chile, to discuss the details…
The project, chosen as “The Best Patent in Latin America”, is registered in the National Institute of Industrial Property (INPI in Spanish) by the discovery of nano antibodies of Llama (Lama glama) capable of neutralizing rotavirus variants origin of viral diarrhea in children and animals….
Bioinnovo, a company formed by INTA and Vetanco, introduced vedevax BLOCK to the market. It is the first recombinant vaccine against a virus present in 90% of establishments, which causes more than 42,000 abortions every year. Bovine Viral Diarrhea virus (BVDV) has a great impact on local livestock production and…
On December 7, at the Cultural Center of Sciences, Buenos Aires, Argentina, more than 400 people participated in the meeting “Agro 2030: Innovation for development,” organized by the program “Argentina 2030” of the Presidency of the Cabinet of Ministers, together with INTA and the Argentinian…
Dr Andrés Wigdorovitz, Head of INCUINTA, CICVyA, INTA, CONICET’s Head Researcher, Bioinnovo’ Scientific Director, gave an exclusive interview to Canal Rural. Click here to watch the interview